Not logged inBH-30236, a Novel Macrocyclic Clk Inhibitor Modulating Aberrant RNA Splicing, Demonstrates Potent Anti-Cancer Activity Against Myeloid Malignancies
Deng, Wei; Jiang, Ping; Li, Danan; Zhai, Dayong; Ling, Nancy; Wang, Zhenping; Hu, Yue; Rogers, Evan; Darjania, Levan; Whitten, Jeff; Shao, Jesse; Montalban, Antonio; Rui, Eugene; Cui, J. Jean .png)
Share.png)
SaveNovel Multikinase Clk Inhibitor BH-30236 Targets Hematological Malignancies through Alternative Splicing RegulationLing, Nancy; Sims, Gregory; Jiang, Ping; Deng, Wei; Zhai, Dayong; Li, Danan; Wang, Zhenping; Hu, Yue; Wang, Eric; Graber, Armin; Cui, J. Jean Share Save Discovery of BH-30236: A novel macrocyclic CLK inhibitor targeting alternative splicing in cancersCui, J. Jean; Jiang, Ping; Deng, Wei; Zhai, Dayong; Ling, Nancy; Li, Danan; Wang, Zhenping; Hu, Yue; Darjania, Levan; Whitten, Jeff; Rogers, Evan; Rui, Eugene Share Save Share Save Share Save TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant MutationsMurray, Brion W.; Zhai, Dayong; Deng, Wei; Zhang, Xin; Ung, Jane; Nguyen, Vivian; Zhang, Han; Barrera, Maria; Parra, Ana; Cowell, Jessica; Lee, Dong J.; Aloysius, Herve; Rogers, Evan Share Save TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitorsCui, J. Jean; Rogers, Evan; Zhai, Dayong; Deng, Wei; Ung, Jane; Nguyen, Vivian; Zhang, Han; Zhang, Xin; Parra, Ana; Barrera, Maria; Lee, Dong; Murray, Brion Share Save Share Save Share Save TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signalingZhai, Dayong; Rogers, Evan; Deng, Wei; Zhang, Xin; Lee, Dong; Ung, Jane; Zhang, Han; Liu, Jing; Lu, Yuelie; Huang, John; Graber, Armin; Zimmerman, Zach; Lim, John; Whitten, Jeffrey; Cui, J. Jean Share Save Share Save TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responsesDeng, Wei; Zhai, Dayong; Rogers, Evan; Zhang, Xin; Lee, Dong; Ung, Jane; Zhang, Han; Liu, Jing; Lu, Yuelie; Huang, John; Graber, Armin; Zimmerman, Zach; Lim, John; Whitten, Jeffrey; Cui, J. Jean Share Save Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutationsDrilon, Alexander; Zhai, Dayong; Deng, Wei; Zhang, Xin; Lee, Dong; Rogers, Evan; Whitten, Jeffrey; Huang, Zhongdong; Graber, Armin; Liu, Juliet; Stopatschinskaja, Shanna; Cui, J. Jean; Kim, Dong-Wan; Cho, Byoung Chul; Doebele, Robert C.; Ou, Sai-Hong Ignatius; Lee, Jeeyun; Shaw, Alice T. Share Save Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front MutationsDrilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lees, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahns, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T. Share Save Share Save TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMTZhai, Dayong; Deng, Wei; Rogers, Evan; Huang, Zhongdong; Whitten, Jeffrey; Lim, John; Li, Yishan; Cui, J. Jean Share Save TPX-0005, a highly potent TRK inhibitor, effectively overcomes clinical-resistance TRK mutations including solvent front mutants TRKA G595R, TRKB G639R, and TRKC G623RCui, J. Jean; Zhai, Dayong; Deng, Wei; Rogers, Evan; Huang, Zhongdong; Whitten, Jeffrey; lim, John; Li, Yishan Share Save TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026MCui, J. Jean; Zhai, Dayong; Deng, Wei; Rogers, Evan; Huang, Zhongdong; Whitten, Jeffrey; Lim, John; Li, Yishan Share Save Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
